

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for any securities in Hong Kong or elsewhere, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or invitation to subscribe for securities, and is provided for information only. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession the information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdictions. Securities referred to in this announcement have not been issued, registered in accordance with any securities laws and regulations or allowed to be offered to public or to circulate in Hong Kong or elsewhere. No representation is made that any such securities will be issued or so registered or allowed to be offered to the public or circulated in Hong Kong or elsewhere.



INSIDE INFORMATION

CONFIDENTIAL SUBMISSION OF DRAFT REGISTRATION STATEMENT ON FORM F-1 AND UPDATE ON PROPOSED DUAL LISTING IN THE UNITED STATES

This announcement is made by IVD Medical Holding Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 14 July 2025 regarding the resolution of the Company to pursue a proposed dual primary listing (the “**Proposed Dual Listing**”) on the NASDAQ Stock Market in the United States through a proposed initial public offering of American Depositary Shares (the “**ADS**”) representing new ordinary shares (the “**Shares**”) of the Company to be issued (the “**Proposed Offering**”).

The Board of the Company (the “**Board**”) is pleased to announce that on 29 September 2025 (Eastern Time of the United States), the Company confidentially filed a draft registration statement on Form F-1 with the United States Securities and Exchange Commission (the “**SEC**”) in connection with the Proposed Offering.

The actual number of ADS to be offered, the Shares represented by the ADSs, and the price range have not yet been determined and will depend on market conditions, investor demand, and final negotiations with the underwriters. The Proposed Offering is expected to commence after the SEC completes its review process and is subject to compliance with relevant regulatory requirements and market conditions.

The Proposed Dual Listing in the United States represents a significant step in the Group's global strategic expansion and is expected to deliver multiple positive impacts for the Company:

- Expanding global financing channels: Access to one of the world's largest and deepest capital markets is anticipated to attract more long-term investors worldwide focused on biotechnology and healthcare aspects, providing robust capital support for the Company's ongoing research, development and commercialization efforts.
- Enhancing international brand influence: Listing on NASDAQ will further elevate the Company's corporate image and industry recognition in international markets, strengthening communication and collaboration opportunities with global potential partners, customers, and regulatory bodies.
- Enhanced Share Liquidity and Valuation Potential: Establishing cross-market trading mechanisms will broaden the investor base, improve overall share liquidity, and enable the Company's long-term value to be fully reflected in a more international pricing environment.
- Optimizing corporate governance and transparency: Compliance with the United States securities regulations and disclosure requirements will further elevate the Company's governance standards and operational transparency, strengthening its global compliance profile and investor confidence.
- Providing flexibility for future strategic advancement: The dual listing structure offers a more robust capital operation platform and strategic options for potential international collaborations, mergers and acquisitions, and business expansion in the future.

This announcement does not constitute an offer to sell or a solicitation of an offer to purchase any securities in any jurisdiction. Any offering of securities will be made only by means of a prospectus that complies with the registration requirements of the United States Securities Act.

As the Proposed Offering may or may not proceed, shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 30 September 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and five independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement may contain certain forward-looking statements that reflect the Company's beliefs, plans or expectations about the future. These statements are based on a number of assumptions, current estimates and projections, and subject to inherent risks, uncertainties and other factors which may or may not be beyond the Company's control. The actual outcomes may differ. Nothing contained in these statements is, or shall be, relied upon as any assurance, representation or warranty otherwise. Neither the Company nor its directors, staff, agents, advisers or representatives assume any responsibility to update, supplement, correct these statements or adapt them to future events.

If there are any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.